Genmab picked up another kick ass milestone from J&J on daratumumab's Phase II.
Genmab banks $22M from J&J as myeloma drug ticks forward
March 27, 2014 | By Damian Garde
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson ($JNJ). J&J signed a deal worth up to $1.1 billion to get its hands on global rights to the drug, taking an $80 million equity stake in Genmab and handing over a $55 million upfront payment. Daratumumab is a CD38 antibody with potential in leukemia and lymphoma, and the drug picked up the FDA's coveted breakthrough therapy designation for multiple myeloma last year.
Article HERE
- Forums
- ASX - By Stock
- PAB
- on another note...
on another note...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $6.172M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $155 | 51.73K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
34 | 30795208 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 22489307 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
34 | 30795208 | 0.003 |
27 | 37131332 | 0.002 |
12 | 51351998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 22489307 | 15 |
0.005 | 10004512 | 8 |
0.006 | 7701466 | 6 |
0.007 | 6601356 | 5 |
0.008 | 790910 | 3 |
Last trade - 10.06am 10/10/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online